Skip to main content
. Author manuscript; available in PMC: 2014 May 20.
Published in final edited form as: J Thromb Haemost. 2013 Jun;11(6):1032–1042. doi: 10.1111/jth.12184

Table 2.

Cost effectiveness and projected model outputs for the two treatment strategies for a deep vein thrombosis

Output Treatment strategy
Standard treatment* CDT in addition to standard treatment
Costs, $ 51 866 64 709
QALYs 31.68 32.31
ICER, $/QALY gained Reference 20 429
Life expectancy, years 30.9 30.8
Patients who developed any PTS, % 62.5 44.0
Patients who developed severe PTS, % 7.6 3.3
Fatal bleeding, % 5.5 5.9
Fatal recurrent venous thromboembolism, % 4.2 3.9

QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio; CDT, catheter-directed thrombolysis; PTS, post-thrombotic syndrome.

*

Standard treatment included 6 months of anticoagulation and 24 months of compression therapy.